All News

Results from a phase 2 trial of temozolomide or temozolomide plus capecitabine showed promising efficacy of the regimens for patients with advanced pancreatic neuroendocrine tumors.

At ASCO 2022, Jonathan S. Zager, MD, spoke about the phase 3 FOCUS trial which analyzed patients with hepatic-dominant ocular melanoma receiving percutaneous hepatic perfusion with melphalan or best alternative care.

Guidelines from the American Society for Radiation Oncology on the use of radiation therapy for patients with IDH-mutant glioma included strong recommendations for close surveillance in IDH-mutant, 1p/19q codeleted, WHO grade 2 oligodendroglioma with no high-risk features and adjuvant radiotherapy for those with WHO grade 3 disease.

At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.

Findings from a pooled analysis indicated that reductions in ctDNA were associated with improved clinical benefit across multiple end points in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.

Akihiro Ohba, MD, discussed the potential benefits of T-DXd in HER2-expressing biliary tract cancer.

Ulka N. Vaishampayan, MBBS, discussed the potential benefits of oral docetaxel plus ritonavir in metastatic castration-resistant prostate cancer.

Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.

Ranjit Nair, MD, discusses the promise of sugemalimab, both as a single-agent and as part of a combination regimen, in patients with relapsed/refractory extranodal natural killer/T-cell lymphoma.

Eric J. Sherman, MD, discussed the effects of using the MEK inhibitor trametinib in combination with paclitaxel in metastatic anaplastic thyroid cancer.

Results from a phase 2 study highlighted a tolerable safety profile when patients with mismatch repair proficient endometrial cancer were treated with avelumab plus talazoparib.

Treatment with adagrasib monotherapy yielded an overall response rate of 42.9% in patients with KRAS G12C–mutated advanced/metastatic non–small cell lung cancer, according to Alexander I. Spira, MD, PhD, FACP.

Superior survival were observed across all efficacy outcomes for patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel compared with standard of care.

Results from the phase 2 ExIST trial indicated that the addition of galunisertib to neoadjuvant chemoradiotherapy for patients with locally advanced rectal cancer resulted in an improvement in responses.

Community health worker–led interventions appeared to improve outcomes among patients with newly diagnosed advanced-stage or recurrent solid and hematologic cancers.

Angela DeMichele, MD, MSCE, discussed the results of the phase 2 I-SPY2 trial in patients with early breast cancer

Patients undergoing complex oncologic surgery for head and neck cancer appeared to have shorter hospital stays when using a multiprofessional assessment and information day compared with those who did not.

Angela DeMichele, MD, MSCE, discussed how the phase 2 I-SPY2 trial in patients with early breast cancer is informing patient therapy decisions in difficult-to-treat situations.

A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.

Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.

Patients with locally advanced or metastatic biliary tract cancer can now receive treatment with durvalumab plus gemcitabine following the combination’s approval by the FDA.

Results from a phase 3 trial show similar results in regard to overall survival when patients with advanced pancreatic ductal adenocarcinoma were treated with either folinic acid, fluorouracil, irinotecan, oxaliplatin or gemcitabine/nab-paclitaxel in the first line.

Findings from a study revealed a notable reduction in the risk of prostate cancer–specific mortality in Black United States veterans who underwent prostate-specific antigen screening, highlighting the potential importance of undergoing annual screenings in this patient population.

Blood circulating soluble proteins may be an effective and accessible biomarker for predicting response to immunotherapy among patients with squamous cell lung cancer.

Kami J. Maddocks, MD, talks CAR T-cell therapy approvals for the treatment of relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma plus a new treatment supplanting R-CHOP.

Overall survival was significantly improved when elotuzumab was added to pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and proteasome inhibitors

The phase 1/2 Neo-PATH trial show promising pathological complete response rates and moderate toxicity in patients with stage III or III ERBB2-positive breast cancer when treated with pertuzumab, atezolizumab, trastuzumab, and docetaxel.

Three months of neoadjuvant chemotherapy may downstage early-stage rectal cancer and thereby reduce the need for total mesorectal excisions (TMEs), resulting in higher rates of organ preservation.

In an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.

Christine Parseghian, MD, discussed the effects of rechallenging patients with a prior response to EGFR inhibition with panitumumab plus or minus the MEK inhibitor trametinib in RAS/BRAF wildtype, microsatellite stable colorectal cancer.